Study details
Enrolling now
Orexin Receptor Antagonism for Alcohol Use Disorder
Ohio State University
NCT IDNCT07214207ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
250
Study length
about 4.8 years
Ages
18–65
Locations
1 site in OH
What this study is about
Researchers are testing if suvorexant, a drug that blocks orexin receptors, can help people with alcohol use disorder. The trial will compare suvorexant to a placebo (a fake pill) over 8 weeks to see if suvorexant reduces alcohol cravings and stress-related drinking.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Placebo
- 2.Take Suvorexant 10 mg
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Oral
How treatment is administered
Treatment Assignment
Randomized & Blinded
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
suvorexant
Drug routes
oral (Oral Tablet)
Body systems
Psychiatry / Mental Health